Want to see RCKT full AI Analyst Report?
Rocket Pharmaceuticals (RCKT) Ratios
Rocket Pharmaceuticals Ratios
RCKT's free cash flow for Q2 2026 was $-39.62M. For the 2026 fiscal year, RCKT's free cash flow was decreased by $-8.00K and operating cash flow was $-39.61M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 |
| Quick Ratio | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 |
| Cash Ratio | 2.57 | 4.02 | 1.15 | 3.59 | 10.50 |
| Solvency Ratio | -3.98 | -3.87 | -3.23 | -3.47 | -3.87 |
| Operating Cash Flow Ratio | -6.29 | -5.15 | -4.02 | -4.55 | -5.47 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 139.51M | $ 313.72M | $ 304.45M | $ 301.94M | $ 349.76M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 |
| Debt-to-Equity Ratio | 0.09 | 0.06 | 0.05 | 0.05 | 0.05 |
| Debt-to-Capital Ratio | 0.08 | 0.05 | 0.05 | 0.04 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.19 | 1.14 | 1.15 | 1.13 | 1.09 |
| Debt Service Coverage Ratio | -111.16 | -131.22 | -126.20 | -111.94 | -26.80 |
| Interest Coverage Ratio | -120.84 | -144.86 | -138.48 | -117.52 | -28.40 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.24 | 0.29 | 0.32 | 0.36 | 0.45 |
| Net Debt to EBITDA | 0.25 | 0.56 | 0.13 | 0.55 | 1.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.64% | 94.71% | 94.58% | 98.89% | 101.09% |
| Return on Assets (ROA) | -67.52% | -49.03% | -43.37% | -40.21% | -34.02% |
| Return on Equity (ROE) | -80.49% | -55.86% | -49.86% | -45.31% | -37.18% |
| Return on Capital Employed (ROCE) | -76.11% | -56.10% | -50.14% | -43.76% | -35.22% |
| Return on Invested Capital (ROIC) | -75.38% | -55.77% | -49.88% | -43.55% | -35.03% |
| Return on Tangible Assets | -83.84% | -55.84% | -48.92% | -45.56% | -36.26% |
| Earnings Yield | -57.20% | -21.71% | -9.75% | -16.64% | -12.25% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.71 | -2.21 | -2.32 | -2.61 | -1.92 |
| Free Cash Flow Per Share | -1.71 | -2.27 | -2.52 | -2.74 | -2.04 |
| Dividend Paid and CapEx Coverage Ratio | -431.85 | -35.78 | -11.83 | -20.67 | -15.70 |
| Capital Expenditure Coverage Ratio | -431.85 | -35.78 | -11.83 | -20.67 | -15.70 |
| Operating Cash Flow Coverage Ratio | -7.64 | -8.23 | -7.78 | -7.79 | -5.36 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -48.83% | -18.09% | -8.40% | -14.00% | -9.34% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.75 | -4.60 | -10.25 | -6.01 | -8.16 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.41 | 2.57 | 5.11 | 2.72 | 3.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.05 | -5.53 | -11.91 | -7.14 | -10.71 |
| Price-to-Operating Cash Flow Ratio | -2.05 | -5.68 | -12.92 | -7.49 | -11.39 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | 0.71 | 0.98 | -0.28 | -1.29 |
| Enterprise Value Multiple | -1.60 | -4.26 | -10.51 | -5.69 | -7.42 |
| Enterprise Value | 337.36M | 1.05B | 2.49B | 1.22B | 1.17B |
| EV to EBITDA | -1.60 | -4.26 | -10.51 | -5.69 | -7.42 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.77 | -4.89 | -11.76 | -6.51 | -9.08 |
| EV to Operating Cash Flow | -1.78 | -5.02 | -12.76 | -6.83 | -9.66 |
| Tangible Book Value Per Share | 1.92 | 4.21 | 5.10 | 6.23 | 6.70 |
| Shareholders’ Equity Per Share | 2.49 | 4.89 | 5.86 | 7.19 | 7.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.01 | 1.01 | 1.01 | 1.04 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | 0.81 | 0.79 | 0.80 | 0.72 |
Currency in USD